Skip to main content
Fig. 6 | Molecular Medicine

Fig. 6

From: Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression

Fig. 6

Quantitative real-time PCR indicated that the upregulation of the expression of osteoclast‑specific genes induced by RANKL was suppressed by ZOL treatment (*P value < 0.05 vs. NC group; #P value < 0.05 vs. RANKL group; ^P value < 0.05 vs. RANKL + ZOL + Scramble control group). a ZOL treatment inhibited RANKL-induced increase in the number of human osteoclast precursor cells, which was obstructed by the knockdown of miR-302, miR-101 and miR-145. b ZOL treatment inhibited RANKL-induced increase of RNA expression of CTR, which was obstructed by the knockdown of miR-302, miR-101 and miR-145. c ZOL treatment inhibited RANKL-induced increase of RNA expression of DC-STAMP, which was obstructed by the knockdown of miR-302, miR-101 and miR-145. d ZOL treatment inhibited RANKL-induced increase of RNA expression of RANK, which was obstructed by the knockdown of miR-302, miR-101 and miR-145. e ZOL treatment inhibited RANKL-induced increase of RNA expression of TRAP, which was obstructed by the knockdown of miR-302, miR-101 and miR-145. f ZOL treatment inhibited RANKL-induced increase of RNA expression of c-fos, which was obstructed by the knockdown of miR-302, miR-101 and miR-145. g ZOL treatment inhibited RANKL-induced increase of RNA expression of NFATc1, which was obstructed by the knockdown of miR-302, miR-101 and miR-145

Back to article page